Cerebrospinal fluid (CSF) samples are increasingly being used for genomic profiling of brain tumors, offering a less invasive alternative to tissue biopsies. CSF samples provide a higher signal-to-noise ratio for detecting tumor-derived cell-free DNA (cfDNA) compared to plasma samples, making them particularly useful for …
ASCO to shine light on multimodal AI models: Plus, melanoma diagnostics and gastroesophageal cancer targets
The upcoming ASCO 2026 meeting will focus on the clinical application of AI in cancer care, emphasizing multimodal AI models that integrate pathology, radiology, molecular data, and liquid biopsy.
SPONSORED ROUNDTABLES
Thermo Fisher Scientific’s SwiftArrayStudio microarray analyzer was developed in response to customer needs for simpler workflows, more consistent turnaround times, and lower operational burden in genomics labs.
CAP TODAY RECOMMENDS
February 2026—Prepared with expert insight from Anil Parwani, MD, PhD; Scott Hammond; and Melinda Schumacher, MD, Grundium’s white paper describes, from a pathologist’s perspective, how compact WSI systems can shorten consult turnaround times and reduce variability, improve access to subspecialty review without adding travel or courier burden, enhance community pathologists’ professional satisfaction and confidence, support scalable, secure, and validated workflows and lay the foundation for AI and advanced analytics as digital adoption grows. Download the white paper here.
Interactive Product Guides
Use our comprehensive guides to view and compare instruments and software systems feature by feature.
FEATURED GUIDE: Billing
Laboratory and pathology billing face challenges from reimbursement threats, downcoding, denials, and prior authorizations.
PRODUCT GUIDE ROUNDTABLES
MARKETPLACE
August 2025—Waters Corp. announced it has acquired Halo Labs. Halo Labs’ Aura platform, which features a highly differentiated technology that performs full spectrum particle analysis, is complementary to the Waters light-scattering detection solutions from its Wyatt Technology portfolio. The subvisible particle technology unlocks additional insights when characterizing external particles used to amplify CAR T cells for cell therapy. By acquiring Halo Labs, Waters said it will be able to integrate the emerging technology into new and existing large molecule development and QA/QC.